Technical Analysis for TLSI - TriSalus Life Sciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 10.32% | |
| Fell Below 20 DMA | Bearish | 10.32% | |
| Slingshot Bearish | Bearish Swing Setup | 10.32% | |
| Crossed Above 20 DMA | Bullish | 8.98% | |
| Hammer Candlestick | Bullish | 8.98% | |
| Pocket Pivot | Bullish Swing Setup | 8.98% | |
| Gapped Up | Strength | 8.98% | |
| Lower Bollinger Band Touch | Weakness | 8.98% | |
| MACD Bearish Signal Line Cross | Bearish | 22.34% | |
| Stochastic Reached Oversold | Weakness | 22.34% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
| Rose Above Upper Bollinger Band | about 1 hour ago |
| Up 5% | about 1 hour ago |
| Up 10% | about 1 hour ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Pancreatic Cancer Colorectal Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Immunotherapy Immunotherapies Pancreatic Cancer Colorectal Cancer Hepatology Hepatocellular Carcinoma Uveal Melanoma Cholangiocarcinoma Intrahepatic Cholangiocarcinoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.42 |
| 52 Week Low | 3.33 |
| Average Volume | 37,137 |
| 200-Day Moving Average | 6.85 |
| 50-Day Moving Average | 4.27 |
| 20-Day Moving Average | 4.10 |
| 10-Day Moving Average | 4.17 |
| Average True Range | 0.35 |
| RSI (14) | 47.09 |
| ADX | 16.66 |
| +DI | 14.18 |
| -DI | 19.26 |
| Chandelier Exit (Long, 3 ATRs) | 3.60 |
| Chandelier Exit (Short, 3 ATRs) | 4.67 |
| Upper Bollinger Bands | 4.49 |
| Lower Bollinger Band | 3.70 |
| Percent B (%b) | 0.47 |
| BandWidth | 19.17 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.0009 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.67 | ||||
| Resistance 3 (R3) | 4.68 | 4.49 | 4.57 | ||
| Resistance 2 (R2) | 4.49 | 4.34 | 4.48 | 4.53 | |
| Resistance 1 (R1) | 4.28 | 4.24 | 4.18 | 4.27 | 4.50 |
| Pivot Point | 4.09 | 4.09 | 4.04 | 4.08 | 4.09 |
| Support 1 (S1) | 3.88 | 3.94 | 3.79 | 3.87 | 3.64 |
| Support 2 (S2) | 3.69 | 3.84 | 3.69 | 3.61 | |
| Support 3 (S3) | 3.48 | 3.69 | 3.57 | ||
| Support 4 (S4) | 3.47 |
